STOCK TITAN

Arbutus Biopharm - ABUS STOCK NEWS

Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.

Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical leader advancing novel therapies for chronic hepatitis B through RNA interference and lipid nanoparticle delivery systems. This page provides investors and industry observers with timely updates on the company’s scientific progress, regulatory milestones, and strategic partnerships.

Access consolidated news coverage of ABUS’s clinical trials, patent developments, and collaborative research initiatives. Our repository includes press releases on drug candidate advancements, financial disclosures, and peer-reviewed study outcomes – all essential for tracking this innovator’s pursuit of HBV functional cures.

Key updates cover three critical areas: clinical-stage developments targeting viral suppression, technology licensing agreements leveraging proprietary LNP platforms, and research publications validating therapeutic approaches. Regular monitoring ensures you stay informed about ABUS’s role in reshaping infectious disease treatment paradigms.

Bookmark this page for direct access to verified updates from Arbutus Biopharma and third-party analyses. Check back frequently to track how ABUS’s dual focus on antiviral therapies and delivery technologies positions it within the competitive biopharmaceutical landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
conferences earnings
-
Rhea-AI Summary
Arbutus Biopharma appoints Melissa V. Rewolinski, PhD, to its board of directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News
Rhea-AI Summary
Arbutus Biopharma announces the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Dr. Sims has played a key role in the development of AB-729, the company's lead therapeutic, and will lead the clinical team. Mr. Naftzger brings over a decade of experience as in-house general counsel for life science companies. Arbutus also thanks Dr. Elizabeth Howard for her contributions and announces the grant of an option to Mr. Naftzger as an inducement award.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary
Arbutus Biopharma to participate in fireside chat at Jefferies Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
Arbutus Biopharm

Nasdaq:ABUS

ABUS Rankings

ABUS Stock Data

605.08M
149.50M
22.26%
55.34%
4.44%
Biotechnology
Pharmaceutical Preparations
Link
United States
WARMINSTER